68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
NCT02162446 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2019-10-02
Summary
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
Interventions
- DRUG
-
satoreotide trizoxetan
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-06-30
- Primary Completion
- 2015-06-30
- Completion
- 2015-06-30
Countries
- Switzerland
Study Locations
More Related Trials
-
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
NCT05459844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer
NCT01830270 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
NCT06885034 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer
NCT01305993 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
NCT00080002 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
NCT00675194 ·Status: COMPLETED ·Phase: PHASE2
-
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
NCT00427349 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
NCT00800969 ·Status: WITHDRAWN ·Phase: PHASE2
-
68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours
NCT06155994 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis
NCT02291211 ·Status: UNKNOWN ·Phase: PHASE2
-
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
NCT03812939 ·Status: UNKNOWN
-
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
NCT03168594 ·Status: TERMINATED ·Phase: PHASE2
-
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
NCT04713202 ·Status: WITHDRAWN ·Phase: PHASE2
-
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
NCT01573468 ·Status: UNKNOWN ·Phase: PHASE2
-
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
NCT06345079 ·Status: RECRUITING ·Phase: PHASE2
-
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
NCT06505395 ·Status: RECRUITING ·Phase: PHASE2
-
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
NCT04915144 ·Status: WITHDRAWN ·Phase: PHASE2
-
SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy
NCT02396498 ·Status: UNKNOWN ·Phase: PHASE3
-
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
NCT06759064 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
NCT07314164 ·Status: RECRUITING
-
Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer
NCT04826107 ·Status: UNKNOWN ·Phase: PHASE2
-
Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
NCT05140746 ·Status: RECRUITING ·Phase: NA
-
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence
NCT07139951 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
NCT01040312 ·Status: COMPLETED
-
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
NCT07304258 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2